Dumouchel David 4
4 · NYER MEDICAL GROUP INC · Filed May 7, 2010
Insider Transaction Report
Form 4
Dumouchel David
Director
Transactions
- Conversion
Common Stock
2010-02-22$1.84/sh+163,044$300,001→ 282,609 total - Exercise of In-Money
Common Stock
2010-05-03$1.49/sh+8,000$11,920→ 334,209 total - Conversion
Common Stock
2010-02-22$1.84/sh+43,600$80,224→ 326,209 total - Conversion
Convertible Note
2010-02-22→ 0 totalExercise: $1.84From: 2009-02-04Exp: 2011-02-04→ Common Stock (163,044 underlying) - Conversion
Series 2 Class B Preferred Stock
2010-02-22−400→ 0 totalExercise: $1.84→ Common Stock (43,600 underlying) - Exercise of In-Money
Common Stock
2010-05-03$1.49/sh+12,000$17,880→ 346,209 total - Exercise of In-Money
Stock Option (right to buy)
2010-05-03−8,000→ 0 totalExercise: $1.49Exp: 2018-02-03→ Common Stock (8,000 underlying) - Exercise of In-Money
Stock Option (right to buy)
2010-05-03−12,000→ 0 totalExercise: $1.49From: 2009-02-04Exp: 2018-02-03→ Common Stock (12,000 underlying)
Footnotes (3)
- [F1]The Series 2 Class B Preferred Stock is convertible at the option of the shareholder in the event of a merger or sale of Nyer Medical Group, Inc., or on or after February 4, 2011.
- [F2]The Series 2 Class B Preferred Stock is subject to mandatory conversion on or after February 4, 2011, so long as there are no events of default existing under certain of the Company's indebtedness and there is an effective resale registration statement filed with respect to the shares of common stock to be issued upon conversion.
- [F3]Options for 2,000 shares are exercisable on each of 06/30/2008, 12/31/2008, 06/30/2009 and 12/31/2009.